Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunityTim Bognàr, Imke H. Bartelink, Christopher C. Dvorak et al.|Blood Advances|2024Cited by 13
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimenTim Bognàr, Arief Lalmohamed, Jurjen S. Kingma et al.|Bone Marrow Transplantation|2023Cited by 11
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen.Tim Bognàr, Arief Lalmohammed, Jurjen S. Kingma et al.|Research Square|2023Cited by 6
Busulfan Exposure Target Attainment in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: A Single Day Versus a Multiple Day Therapeutic Drug Monitoring RegimenTim Bognàr, Arief Lalmohamed, Imke H. Bartelink et al.|Transplantation and Cellular Therapy|2024Cited by 4
Evaluation of standard fludarabine dosing and corresponding exposures in infants and young children undergoing hematopoietic cell transplantationJulia E. Möhlmann, Caroline A. Lindemans, Marc Bierings et al.|Bone Marrow Transplantation|2024Cited by 1